Low-Dose 5HT Agonist Compositions for Cognitive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals targeting serotonin pathways for treating mood disorders have long onset times, severe side effects, and poor efficacy, posing risks to users, while psilocybin therapy is limited by adverse effects such as hallucinations and physical discomfort.
Innovation Solution
Development of low-dose pharmaceutical compositions containing 5HT receptor agonists like psilocin or psilocybin, administered in controlled release formulations to achieve therapeutic effects without adverse side effects, with plasma concentrations below 6 ng/mL to manage conditions like depression and anxiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceuticals targeting serotonin pathways are used to treat mood disorders, then therapeutic effects are achieved, but severe side effects and long onset times occur
Solution Approach 1:
The patent changes the key parameter of serotonin receptor activation from conventional partial agonism to selective 5-HT2A receptor agonism with specific binding affinity characteristics. This parameter change enables therapeutic efficacy while avoiding the side effects associated with conventional serotonin-targeting pharmaceuticals that affect multiple receptor subtypes
Solution Approach 2:
The patent introduces a specific molecular structure (5-HT2A selective agonist) as an intermediary that selectively activates only the desired receptor subtype. This intermediary molecule acts as a precise mediator between the administered compound and the therapeutic effect, preventing off-target interactions that cause side effects
2Reliability
If psilocybin is administered at high doses to achieve therapeutic effects, then treatment efficacy improves, but adverse effects such as hallucinations and physical discomfort increase
Solution Approach 1:
The patent applies partial action by administering sub-psychedelic doses of 5-HT2A selective agonists that provide therapeutic benefits without reaching the threshold for adverse psychedelic effects. This partial activation achieves the desired therapeutic outcome while avoiding excessive stimulation that causes hallucinations and physical discomfort
Solution Approach 2:
The patent changes the dosage parameter from conventional high-dose psilocybin administration to low-dose selective 5-HT2A agonist administration. This parameter change maintains therapeutic efficacy while eliminating the adverse effects associated with high-dose psychedelic compounds
3Ease of operation
If conventional antidepressants are used to treat mood disorders, then commercial availability and ease of use are improved, but onset time increases and efficacy decreases
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the treatment by using 5-HT2A selective agonists with rapid absorption and onset characteristics. This parameter change enables the treatment to work quickly like acute interventions while maintaining the ease of oral administration typical of conventional antidepressants
Data Source
AI summary
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.